No Data
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $150
RBC Lifts Price Target on Axsome Therapeutics to $132 From $131, Keeps Outperform Rating
Axsome Therapeutics Is Maintained at Outperform by Baird
No Data
No Data